Holen Sie sich die Stockscreener-App
667.26
0.64%
4.38
Schlusskurs vom Vortag:
$662.88
Offen:
$660.8
24-Stunden-Volumen:
286.88K
Relative Volume:
0.30
Marktkapitalisierung:
$69.91B
Einnahmen:
$14.92B
Nettoeinkommen (Verlust:
$4.42B
KGV:
16.26
EPS:
41.0422
Netto-Cashflow:
$3.79B
1W Leistung:
+1.96%
1M Leistung:
+8.27%
6M Leistung:
-16.25%
1J Leistung:
+20.73%
1-Tages-Spanne:
$660.80
$668.83
1-Wochen-Bereich:
$637.72
$677.92
52-Wochen-Spanne:
$541.00
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
666.86 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
487.84 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
912.96 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.52 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
192.74 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
REGN Maintained by Piper Sandler -- Price Target Lowered to $854 - GuruFocus
REGN Maintained by Morgan Stanley -- Price Target Lowered to $73 - GuruFocus
Regeneron Narrows Amgen Challenges in Case Over Eylea Biosimilar - Bloomberg Law News
Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut? - Insider Monkey
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $696 to $769 - Moomoo
Regeneron Pharmaceuticals balances growth prospects as a major biotech player. The company continues - Ad-hoc-news.de
Regeneron Ducks Amgen's Eylea Antitrust Counterclaims - Law360
Form 4 Regeneron Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron director Arthur Ryan sells $130,030 in stock - Investing.com
Regeneron director Arthur Ryan sells $130,030 in stock By Investing.com - Investing.com Canada
Regeneron gains as investors look past one-time Q2 charge and focus on pipeline - Quiver Quantitative
REGN Maintained by RBC Capital -- Price Target Lowered to $696 - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Swedbank AB - MarketBeat
Regeneron Pharmaceuticals profile and stock context for US investors - Ad-hoc-news.de
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $696 - Moomoo
REGN Maintained by Truist Securities -- Price Target Lowered to $769 - GuruFocus
Benchmark Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy - MarketBeat
REGN Upgraded by Benchmark -- Price Target Announced at $185 - GuruFocus
RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $696 From $707, Maintains Sector Perform Rating - marketscreener.com
Regeneron Pharmaceuticals (REGN) Could Be 22% Below Fair Value After Cemdisiran Review Win - simplywall.st
Regeneron Pharma 1Q Adj EPS $9.47 >REGN - Moomoo
Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma - Stocktwits
REGN Maintains Buy Rating with HSBC -- Price Target Lowered to $880 - GuruFocus
FDA to fast-track Regeneron drug facility in Saratoga County - Yahoo Finance
Regeneron Pharmaceuticals, Inc. Files Form 8-K with SEC: Key Company Details and Compliance Information - Minichart
Regeneron Pharmaceuticals (REGN) Anticipates $127M R&D Charge in Q2 2026 - GuruFocus
Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns By Investing.com - Investing.com Canada
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $990 - Moomoo
Regeneron (REGN) warns $127M Q2 IPR&D charge will cut EPS by $1 - Stock Titan
K.J. Harrison & Partners Inc Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN): Investor Outlook With A Strong 27% Potential Upside - DirectorsTalk Interviews
How One Researcher's Personal Study Experience Is Helping Him Better Serve Patients - Clinical Leader
Should Cemdisiran’s Priority Reviews and First-in-Class siRNA Status Require Action From Regeneron (REGN) Investors? - simplywall.st
Regeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiran - Yahoo Finance
Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain - Yahoo Finance
Simplify Asset Management Inc. Has $8.42 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 11,050 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions - simplywall.st
REGNRegeneron Pharmaceuticals Inc Latest SEC Filings - Finviz
Janney Montgomery Scott LLC Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
New data strengthen cemdisiran case in generalized MG - The Pharma Letter
Regeneron Pharmaceuticals (REGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceu - The National Law Review
Regeneron Pharma strengthens its position in biotech. Focus on long-term growth and innovation - AD HOC NEWS
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program - BioSpace
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):